Canton Hathaway LLC Reduces Stake in Moderna, Inc. (NASDAQ:MRNA)

Canton Hathaway LLC cut its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 57.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 601 shares of the company’s stock after selling 820 shares during the period. Canton Hathaway LLC’s holdings in Moderna were worth $40,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Intrinsic Value Partners LLC boosted its position in shares of Moderna by 91.1% in the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after buying an additional 24,505 shares in the last quarter. Banco Santander S.A. acquired a new position in Moderna during the third quarter worth about $3,550,000. John G Ullman & Associates Inc. lifted its holdings in shares of Moderna by 341.3% in the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock valued at $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Finally, Vontobel Holding Ltd. grew its position in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after purchasing an additional 69,313 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research note on Thursday, September 19th. JPMorgan Chase & Co. reduced their price objective on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research report on Monday, November 4th. Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a research report on Monday, November 18th. Sanford C. Bernstein initiated coverage on shares of Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.00.

Moderna Stock Performance

Moderna stock opened at $42.40 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna, Inc. has a 12 month low of $35.80 and a 12 month high of $170.47. The company has a fifty day moving average price of $54.96 and a two-hundred day moving average price of $93.71. The company has a market cap of $16.32 billion, a PE ratio of -7.06 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) EPS. Research analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,930 shares of company stock worth $217,170 over the last ninety days. Company insiders own 15.20% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.